Daxor Corp

Insider buying fuels optimism for Daxor Corp as CEO’s fresh FDA‑cleared blood‑volume‑analysis service meets rising chronic‑disease market demand and reimbursement opportunities.

Insider buying at Daxor Corp signals confidence in its low‑priced medical‑device platform. Discover how this move could unlock value in a growing healthcare segment.

Insider buying by Daxor’s C‑suite signals management confidence in a soon‑to‑launch blood‑volume device that could boost revenue and attract value‑based reimbursement, hinting at a potential rally.